References
- Ali S, Egunsola O, Babar ZUD, et al. Clinical trials in Asia: a World Health Organization database study. Perspect Clin Res. 2019;10(3):121–124.
- Sertkaya A, Wong HH, Jessup A, et al. Key cost drivers of pharmaceutical clinical trials in the United States. Clin Trials. 2016;13(2):117–126.
- Drain PK, Robine M, Holmes KK, et al. Trial watch: global migration of clinical trials. Nat Rev Drug Discov. 2014;13(3):166–167.
- Zhou Q, Chen XY, Yang ZM, et al. The changing landscape of clinical trial and approval processes in China. Nat Rev Clin Oncol. 2017;14(9):577–583.
- Cao Y, Li ZP, Wang CJ, et al. Discussion on the current situation and problems of the development of drug clinical trial institutions in China. Chin J Clin Pharmacol. 2016;32(16):1512–1513.
- Li N, Huang HY, Wu DW, et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009–18: a systematic review. Lancet Oncol. 2019;20(11):e619–e626.
- Announcement on Information Platform for Drug Clinical Trials [Internet]. China: National Medical Products Administration; 2021 [cited 2021 Dec 12]. Available from: http://www.chinadrugtrials.org.cn.
- State Council’s Opinions on Reforming the Review and Approval System for Drugs and Medical Devices [Internet]. China: The State Council; 2021 [cited 2021 Dec 12 ]. Available from: http://www.gov.cn/zhengce/content/2015-08/18/content_10101.htm.
- Announcement of the State Food and Drug Administration on the Self-examination and verification of drug clinical trial data (No. 117 of 2015) [ Internet]. China National Medical Products Administration; 2015 [cited 2021 Dec 12 ]. Available from: https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20150722173601172.html.
- Announcement of Technical Guidelines for Clinical Trial Data Management (No. 112 of 2016) [Internet]. China: National Medical Products Administration; [cited 2021 Dec 12]. Available from: https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/qtggtg/20160729183801891.html.
- Regulations for the Administration of Drug Clinical Trial Institutions (No.101 of 2019) [Internet]. China: National Medical Products Administration; 2021 [cited 2021 Dec 12]. Available from: http://www.gov.cn/gongbao/content/2020/content_5496785.html.
- Cui YZ, Han JX. Defining rare diseases in China. Intractable Rare Dis Res. 2017;6(2):148–149.
- The Guide for Diagnosis and Treatment of Rare Diseases (2019 Version) (in Chinese) [Internet]. China: National Health Commission; 2021 [cited 2021 Dec 12]. Available from: http://www.nhc.gov.cn/yzygj/s7659/201902/61d06b4916c348e0810ce1fceb844333.shtml.
- Wang M. Clinical trials and drug approvals continue to accelerate in China. Lancet Oncol. 2017;18(7):855.
- Parry J. Queue for drug registrations grows longer in China. BMJ. 2015;350:h1596.
- Notice on the Announcement of the First Batch of Rare Diseases Catalog (in Chinese) [Internet]. China: National Health Commission; 2021 [cited 2021 Dec 12]. Available from: http://www.nhc.gov.cn/yzygj/s7659/201806/393a9a37f39c4b458d6e830f40a4bb99.shtml.
- The Opinions on the Evaluation of the Quality and Efficacy of Generic Drugs (No.6) [Internet]. China: The State Council; 2021 [cited 2021 Dec 12]. Available from: http://www.gov.cn/zhengce/content/2016-03/05/content_5049364.htm.
- Bell SA, Tudur SC. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis. 2014;9:170.
- Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2019;394(10204):1145–1158.
- Liu X, Wu S, Sun J, et al. Changes in clinical trials of endocrine disorder and metabolism and nutrition disorder drugs in mainland China over 2010–2019. Pharmacol Res Perspect. 2021;9(2):e00729.